PT027 (albuterol/budesonide) is a potential first-in-class inhaled, fixed-dose combination of the short-acting beta2-agonist albuterol and budesonide, an inhaled corticosteroid.
Breztri will be the first inhaler in AstraZeneca’s portfolio to use ... It is a fixed-dose combination of a corticosteroid ...
Pharmac will also fund osimertinib for people with a type of advanced non-small cell lung cancer. About 20 percent of people with non-small cell lung cancer have a mutation in their cancer that can be ...